Biogen (BIIB) PT Lowered to $351 at Morgan Stanley
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $213.72 +2.19%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 13 | New: 26
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 13 | New: 26
Join SI Premium – FREE
Morgan Stanley analyst Matthew Harrison lowered the price target on Biogen (NASDAQ: BIIB) to $351.00 (from $352.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $55 at H.C. Wainwright
- Venu Holding (VENU) PT Lowered to $8.70 at Freedom Broker
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
